Exosomes neutralize synaptic-plasticity-disrupting activity of Aβ assemblies in vivo

Molecular Brain

Volumn 6, Issue 1, 2013, Pages

  An, Kyongman ^a   Klyubin, Igor ^b   Kim, Youngkyu ^a   Jung, Jung Hoon ^a   Mably, Alexandra J ^c,d   O'Dowd, Sean T ^d,e   Lynch, Timothy ^e   Kanmert, Daniel ^c   Lemere, Cynthia A ^c   Finan, Gina M ^f   Park, Joon Won ^a   Kim, Tae Wan ^f   Walsh, Dominic M ^c   Rowan, Michael J ^b   Kim, Joung Hun ^a  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

^e MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^f NewYork Presbyterian Hospital   (United States)

Author keywords

A ; Alzheimer's disease; Exosomes; PrPC; Synaptic plasticity

Indexed keywords

AMYLOID BETA PROTEIN; PRION PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; EXOSOME; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LONG TERM POTENTIATION; MALE; NERVE CELL PLASTICITY; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; RAT;

AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; CEREBROSPINAL FLUID; DIFFUSION; EXOSOMES; FEMALE; HUMANS; LIGANDS; LONG-TERM POTENTIATION; MALE; MEMBRANE PROTEINS; MICE; NEURONAL PLASTICITY; NEUROPROTECTIVE AGENTS; PRPC PROTEINS; RATS; RATS, WISTAR; SYNAPSES;

EID: 84887392802     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/1756-6606-6-47     Document Type: Article

References (55)

1. Resolving controversies on the path to Alzheimer's therapeutics. Selkoe DJ, Nat Med 2011 17 1060 1065 10.1038/nm.2460 21900936
2. Alzheimer's disease is a synaptic failure. Selkoe DJ, Science 2002 298 789 791 10.1126/science.1074069 12399581 (Pubitemid 35231524)
3. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Hardy J, Selkoe DJ, Science 2002 297 353 356 10.1126/science.1072994 12130773 (Pubitemid 34790756)
4. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Benilova I, Karran E, De Strooper B, Nat Neurosci 2012 15 349 357 10.1038/nn.3028 22286176
5. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, et al. Proc Natl Acad Sci USA 1998 95 6448 6453 10.1073/pnas.95.11.6448 9600986 (Pubitemid 28249033)
6. Interaction between prion protein and toxic amyloid beta assemblies can be therapeutically targeted at multiple sites. Freir DB, Nicoll AJ, Klyubin I, Panico S, Mc Donald JM, Risse E, Asante EA, Farrow MA, Sessions RB, Saibil HR, et al. Nat Commun 2011 2 336 21654636
7. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM, Nature 2009 457 1128 1132 10.1038/nature07761 19242475
8. Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease. Yaar M, Zhai S, Pilch PF, Doyle SM, Eisenhauer PB, Fine RE, Gilchrest BA, J Clin Invest 1997 100 2333 2340 10.1172/JCI119772 9410912 (Pubitemid 27500157)
9. Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. Xie L, Helmerhorst E, Taddei K, Plewright B, Van Bronswijk W, Martins R, J Neurosci Off J Soc Neurosci 2002 22 C221
10. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ, Nat Med 2005 11 556 561 10.1038/nm1234 15834427 (Pubitemid 40685979)
11. Alzheimer's disease brain-derived amyloid-beta-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. Barry AE, Klyubin I, Mc Donald JM, Mably AJ, Farrell MA, Scott M, Walsh DM, Rowan MJ, J Neurosci 2011 31 7259 7263 10.1523/JNEUROSCI.6500-10.2011 21593310
12. Exosomes: composition, biogenesis and function. Thery C, Zitvogel L, Amigorena S, Nat Rev Immunol 2002 2 569 579 12154376 (Pubitemid 37328732)
13. Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? Bellingham SA, Guo BB, Coleman BM, Hill AF, Front Physiol 2012 3 124 22563321
14. Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes. Sharples RA, Vella LJ, Nisbet RM, Naylor R, Perez K, Barnham KJ, Masters CL, Hill AF, FASEB J 2008 22 1469 1478 18171695 (Pubitemid 351656787)
15. Insulin-degrading enzyme sorting in exosomes: a secretory pathway for a key brain amyloid-beta degrading protease. Bulloj A, Leal MC, Xu H, Castano EM, Morelli L, J Alzheimers Dis 2010 19 79 95 20061628
16. Sphingolipid-modulated exosome secretion promotes the clearance of amyloid-beta by microglia. Yuyama K, Sun H, Mitsutake S, Igarashi Y, J Biol Chem 2012 287 10977 10989 10.1074/jbc.M111.324616 22303002
17. Formation of toxic Abeta(1-40) fibrils on GM1 ganglioside-containing membranes mimicking lipid rafts: polymorphisms in Abeta(1-40) fibrils. Okada T, Ikeda K, Wakabayashi M, Ogawa M, Matsuzaki K, J Mol Biol 2008 382 1066 1074 10.1016/j.jmb.2008.07.072 18692507
18. Neuroprotective effect of ganglioside GM1 on the cytotoxic action of hydrogen peroxide and amyloid beta-peptide in PC12 cells. Sokolova TV, Zakharova IO, Furaev VV, Rychkova MP, Avrova NF, Neurochem Res 2007 32 1302 1313 10.1007/s11064-007-9304-2 17401655 (Pubitemid 46988190)
19. Self-assembly of Abeta(1-42) into globular neurotoxins. Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, et al. Biochemistry 2003 42 12749 12760 10.1021/bi030029q 14596589 (Pubitemid 37385806)
20. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Thery C, Amigorena S, Raposo G, Clayton A, Curr Protoc Cell Biol 2006 3 3 22
21. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ, Nature 2002 416 535 539 10.1038/416535a 11932745 (Pubitemid 34288854)
22. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, et al. Nat Med 2008 14 837 842 10.1038/nm1782 18568035
23. Clearing the brain's amyloid cobwebs. Selkoe DJ, Neuron 2001 32 177 180 10.1016/S0896-6273(01)00475-5 11683988 (Pubitemid 33030186)
24. The cellular prion protein and its role in Alzheimer disease. Velayos JL, Irujo A, Cuadrado-Tejedor M, Paternain B, Moleres FJ, Ferrer V, Prion 2009 3 110 117 10.4161/pri.3.2.9135 19556894
25. Enrichment of prion protein in exosomes derived from ovine cerebral spinal fluid. Vella LJ, Greenwood DL, Cappai R, Scheerlinck JP, Hill AF, Vet Immunol Immunopathol 2008 124 385 393 10.1016/j.vetimm.2008.04.002 18501435
26. Packaging of prions into exosomes is associated with a novel pathway of PrP processing. Vella LJ, Sharples RA, Lawson VA, Masters CL, Cappai R, Hill AF, J Pathol 2007 211 582 590 10.1002/path.2145 17334982 (Pubitemid 46502435)
27. Prions prevent neuronal cell-line death. Kuwahara C, Takeuchi AM, Nishimura T, Haraguchi K, Kubosaki A, Matsumoto Y, Saeki K, Matsumoto Y, Yokoyama T, Itohara S, Onodera T, Nature 1999 400 225 226 10.1038/22241 10421360 (Pubitemid 29334128)
28. Differential effects of Phe19 and Phe20 on fibril formation by amyloidogenic peptide A beta 16-22 (Ac-KLVFFAE-NH2). Inouye H, Gleason KA, Zhang D, Decatur SM, Kirschner DA, Proteins 2010 78 2306 2321 10.1002/prot.22743 20544966
29. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Alvarez-Erviti L, Seow Y, Schapira AH, Gardiner C, Sargent IL, Wood MJ, Cooper JM, Neurobiol Dis 2011 42 360 367 10.1016/j.nbd.2011.01.029 21303699
30. Exosomes: the Trojan horses of neurodegeneration. Ghidoni R, Benussi L, Binetti G, Med Hypotheses 2008 70 1226 1227 10.1016/j.mehy.2007.12.003 18226468
31. Mouse neuroblastoma cells release prion infectivity associated with exosomal vesicles. Alais S, Simoes S, Baas D, Lehmann S, Raposo G, Darlix JL, Leblanc P, Biol Cell 2008 100 603 615 10.1042/BC20080025 18422484
32. Accelerated release of exosome-associated GM1 ganglioside (GM1) by endocytic pathway abnormality: another putative pathway for GM1-induced amyloid fibril formation. Yuyama K, Yamamoto N, Yanagisawa K, J Neurochem 2008 105 217 224 10.1111/j.1471-4159.2007.05128.x 18021298 (Pubitemid 351441638)
33. Statins promote the degradation of extracellular amyloid {beta}-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion. Tamboli IY, Barth E, Christian L, Siepmann M, Kumar S, Singh S, Tolksdorf K, Heneka MT, Lutjohann D, Wunderlich P, Walter J, J Biol Chem 2010 285 37405 37414 10.1074/jbc.M110.149468 20876579
34. Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. Cullen WK, Suh YH, Anwyl R, Rowan MJ, Neuroreport 1997 8 3213 3217 10.1097/00001756-199710200-00006 9351645 (Pubitemid 27461369)
35. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH, Nat Neurosci 2005 8 79 84 10.1038/nn1372 15608634 (Pubitemid 41236735)
36. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, Lemere CA, Cullen WK, Peng Y, Wisniewski T, et al. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 2008 28 4231 4237 10.1523/JNEUROSCI.5161-07.2008 18417702
37. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ, J Physiol 2006 572 477 492 10.1113/jphysiol.2005.103754 16469784
38. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. Puzzo D, Privitera L, Leznik E, Fa M, Staniszewski A, Palmeri A, Arancio O, J Neurosci Off J Soc Neurosci 2008 28 14537 14545 10.1523/JNEUROSCI.2692-08.2008
39. Beta-amyloid monomers are neuroprotective. Giuffrida ML, Caraci F, Pignataro B, Cataldo S, De Bona P, Bruno V, Molinaro G, Pappalardo G, Messina A, Palmigiano A, et al. J Neurosci Off J Soc Neurosci 2009 29 10582 10587 10.1523/JNEUROSCI.1736-09.2009
40. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Balducci C, Beeg M, Stravalaci M, Bastone A, Sclip A, Biasini E, Tapella L, Colombo L, Manzoni C, Borsello T, et al. Proc Natl Acad Sci USA 2010 107 2295 2300 10.1073/pnas.0911829107 20133875
41. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Lauren J, Gimbel ZA, Strittmatter SM, J Neurosci Off J Soc Neurosci 2010 30 6367 6374 10.1523/JNEUROSCI.0395-10.2010
42. The prion protein as a receptor for amyloid-beta. Kessels HW, Nguyen LN, Nabavi S, Malinow R, Nature 2010 466 3 E4 discussion E4-5 10.1038/nature09217 20703260
43. Amyloid-beta42 interacts mainly with insoluble prion protein in the Alzheimer brain. Zou WQ, Xiao X, Yuan J, Puoti G, Fujioka H, Wang X, Richardson S, Zhou X, Zou R, Li S, et al. J Biol Chem 2011 286 15095 15105 10.1074/jbc.M110.199356 21393248
44. The Complex PrPc-Fyn Couples Human Oligomeric Abeta with Pathological Tau Changes in Alzheimer's Disease. Larson M, Sherman MA, Amar F, Nuvolone M, Schneider JA, Bennett DA, Aguzzi A, Lesne SE, J Neurosci Off J Soc Neurosci 2012 32 16857 16871 10.1523/JNEUROSCI.1858-12.2012
45. Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues. Chen S, Yadav SP, Surewicz WK, J Biol Chem 2010 285 26377 26383 10.1074/jbc.M110.145516 20576610
46. Alzheimer's disease Abeta assemblies mediating rapid disruption of synaptic plasticity and memory. Klyubin I, Cullen WK, Hu NW, Rowan MJ, Mol Brain 2012 5 25 10.1186/1756-6606-5-25 22805374
47. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, Holtzman DM, Neuron 2008 58 42 51 10.1016/j.neuron.2008.02.003 18400162 (Pubitemid 351467029)
48. Identification and proteomic profiling of exosomes in human cerebrospinal fluid. Street JM, Barran PE, Mackay CL, Weidt S, Balmforth C, Walsh TS, Chalmers RT, Webb DJ, Dear JW, J Transl Med 2012 10 5 10.1186/1479-5876-10-5 22221959
49. Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes. Tauro BJ, Greening DW, Mathias RA, Ji H, Mathivanan S, Scott AM, Simpson RJ, Methods 2012 56 293 304 10.1016/j.ymeth.2012.01.002 22285593
50. Sampling and analysis of cerebrospinal fluid for chronic studies in awake rats. Lai YL, Smith PM, Lamm WJ, Hildebrandt J, J Appl Physiol 1983 54 1754 1757 6409862 (Pubitemid 13060018)
51. Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells. Gutwein P, Stoeck A, Riedle S, Gast D, Runz S, Condon TP, Marme A, Phong MC, Linderkamp O, Skorokhod A, Altevogt P, Clin Cancer Res Off J Am Assoc Cancer Res 2005 11 2492 2501 10.1158/1078-0432.CCR-04-1688 (Pubitemid 40569445)
52. Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Rajendran L, Honsho M, Zahn TR, Keller P, Geiger KD, Verkade P, Simons K, Proc Natl Acad Sci USA 2006 103 11172 11177 10.1073/pnas.0603838103 16837572 (Pubitemid 44156491)
53. Release of exosomes from differentiated neurons and its regulation by synaptic glutamatergic activity. Lachenal G, Pernet-Gallay K, Chivet M, Hemming FJ, Belly A, Bodon G, Blot B, Haase G, Goldberg Y, Sadoul R, Mol Cell Neurosci 2011 46 409 418 10.1016/j.mcn.2010.11.004 21111824
54. Spike bursts increase amyloid-beta 40/42 ratio by inducing a presenilin-1 conformational change. Dolev I, Fogel H, Milshtein H, Berdichevsky Y, Lipstein N, Brose N, Gazit N, Slutsky I, Nat Neurosci 2013 16 587 595 10.1038/nn.3376 23563578
55. The levels of water-soluble and triton-soluble Abeta are increased in Alzheimer's disease brain. McDonald JM, Cairns NJ, Taylor-Reinwald L, Holtzman D, Walsh DM, Brain Res 2012 1450 138 147 22440675